|
|
|||
| |||||||||||||||||||||||||||||||||
(TNF-
) are entering mainstream clinical medicine: antibodies against TNF-
and soluble receptors for TNF-
are being used to treat rheumatoid arthritis and Crohn's disease. A large number of preclinical studies form the scientific basis for these anticytokine-based therapies. In experiments in animals in which a disease involving several cytokines has been induced, administration of neutralizing antibodies or the use of other means to block the biologic activity of a specific cytokine attenuates the effects of the disease or halts its progression.
A novel approach to
References
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |